{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T16:41:59Z","timestamp":1648831319679},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2010,9,24]],"date-time":"2010-09-24T00:00:00Z","timestamp":1285286400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Z. Rheumatol."],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1007\/s00393-009-0584-6","type":"journal-article","created":{"date-parts":[[2010,9,22]],"date-time":"2010-09-22T13:38:11Z","timestamp":1285162691000},"page":"696-701","source":"Crossref","is-referenced-by-count":1,"title":["Lipidstoffwechsel aktuell: statininduzierte Myopathien"],"prefix":"10.1007","volume":"69","author":[{"given":"L.L.","family":"Teichmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Fleck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,9,24]]},"reference":[{"key":"584_CR1","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/BOR.0b013e328010c559","volume":"19","author":"Baer","year":"2007","unstructured":"Baer AN, Wortmann RL (2007) Myotoxicity associated with lipid-lowering drugs. Curr Opin Rheumatol 19:67\u201373","journal-title":"Curr Opin Rheumatol"},{"key":"584_CR2","doi-asserted-by":"crossref","first-page":"III50","DOI":"10.1161\/01.CIR.0000131519.15067.1f","volume":"109","author":"Bellosta","year":"2004","unstructured":"Bellosta S, Paoletti R, Corsini A (2004) Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 109:III50\u2013III57","journal-title":"Circulation"},{"key":"584_CR3","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0163-7258(99)00045-5","volume":"84","author":"Corsini","year":"1999","unstructured":"Corsini A, Bellosta S, Baetta R et al (1999) New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 84:413\u2013428","journal-title":"Pharmacol Ther"},{"key":"584_CR4","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1517\/14740338.3.6.547","volume":"3","author":"Davidson","year":"2004","unstructured":"Davidson MH (2004) Rosuvastatin safety: lessons from the FDA review and post-approval surveillance. Expert Opin Drug Saf 3:547\u2013557","journal-title":"Expert Opin Drug Saf"},{"key":"584_CR5","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/00001648-200109000-00017","volume":"12","author":"Gaist","year":"2001","unstructured":"Gaist D, Rodr\u00edguez LA, Huerta C et al (2001) Lipid-lowering drugs and risk of myopathy: a population-based follow-up study. Epidemiology 12:565\u2013569","journal-title":"Epidemiology"},{"key":"584_CR6","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1001\/jama.292.21.2585","volume":"292","author":"Graham","year":"2004","unstructured":"Graham DJ, Staffa JA, Shatin D et al (2004) Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 292:2585\u20132590","journal-title":"JAMA"},{"key":"584_CR7","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1001\/archinte.165.22.2671","volume":"165","author":"Hansen","year":"2005","unstructured":"Hansen KE, Hildebrand JP, Ferguson EE, Stein JH (2005) Outcomes in 45 patients with statin-associated myopathy. Arch Intern Med 165:2671\u20132676","journal-title":"Arch Intern Med"},{"key":"584_CR8","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.amjcard.2004.08.076","volume":"95","author":"Jones","year":"2005","unstructured":"Jones PH, Davidson MH (2005) Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol 95:120\u2013122","journal-title":"Am J Cardiol"},{"key":"584_CR9","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1161\/CIRCULATIONAHA.106.624890","volume":"114","author":"Kashani","year":"2006","unstructured":"Kashani A, Phillips CO, Foody JM et al (2006) Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation 114:2788\u20132797","journal-title":"Circulation"},{"key":"584_CR10","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S1053-2498(00)00077-2","volume":"19","author":"Keogh","year":"2000","unstructured":"Keogh A, Macdonald P, Kaan A et al (2000) Efficacy and safety of pravastatin vs simvastatin after cardiac transplantation. J Heart Lung Transplant 19:529\u2013537","journal-title":"J Heart Lung Transplant"},{"key":"584_CR11","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/art.23309","volume":"59","author":"Marie","year":"2008","unstructured":"Marie I, Delafen\u00eatre H, Massy N et al (2008) Tendinous disorders attributed to statins: a study on ninety-six spontaneous reports in the period 1990\u20132005 and review of the literature. Arthritis Rheum 59:367\u2013372","journal-title":"Arthritis Rheum"},{"key":"584_CR12","doi-asserted-by":"crossref","first-page":"a2286","DOI":"10.1136\/bmj.a2286","volume":"337","author":"Sathasivam","year":"2008","unstructured":"Sathasivam S, Lecky B (2008) Statin induced myopathy. BMJ 337:a2286","journal-title":"BMJ"},{"key":"584_CR13","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/00005344-200208000-00001","volume":"40","author":"Sinzinger","year":"2002","unstructured":"Sinzinger H, Wolfram R, Peskar BA (2002) Muscular side effects of statins. J Cardiovasc Pharmacol 40:163","journal-title":"J Cardiovasc Pharmacol"},{"key":"584_CR14","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1001\/archinte.163.6.688","volume":"163","author":"Smith","year":"2003","unstructured":"Smith CC, Bernstein LI, Davis RB et al (2003) Screening for statin-related toxicity: the yield of transaminase and creatine kinase measurements in a primary care setting. Arch Intern Med 163:688\u2013692","journal-title":"Arch Intern Med"},{"key":"584_CR15","doi-asserted-by":"crossref","first-page":"69C","DOI":"10.1016\/j.amjcard.2005.12.013","volume":"97","author":"Thompson","year":"2006","unstructured":"Thompson PD, Clarkson PM, Rosenson RS, National Lipid Association Statin Safety Task Force Muscle Safety Expert Panel (2006) An assessment of statin safety by muscle experts. Am J Cardiol 97:69C\u201376C","journal-title":"Am J Cardiol"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-009-0584-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-009-0584-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-009-0584-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T12:21:19Z","timestamp":1636546879000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-009-0584-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,24]]},"references-count":15,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["584"],"URL":"https:\/\/doi.org\/10.1007\/s00393-009-0584-6","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,24]]}}}